Synthesis and Biological Evaluation of Novel 5,5-Diphenylimidazolidine Derivatives with Anticonvulsant Activity

Background

A heterocyclic hydrocarbon having a 5, 5-diphenylimidazolidine heterocyclic ring that possesses distinctive fundamental structural characteristics. It is a fused ring of aromatic di-benzene and imidazolidine. The flexible heterocyclic molecules in 5, 5-diphenylimidazolidine that have two nitrogen atoms. The biological activity of the 5, 5-diphenylimidazolidine ring and its derivatives is significant and encouraging. We produce a variety of 4-(chloromethoxy)- 3-[2,4-dioxo-5,5-diphenylimidazolidine-1-yl) carbonyl] benzene sulfonic acid and its derivatives in this investigation. In literature survey and molecular docking; it was confirmed that 5, 5-diphenylimidazolidine-2,4-dione gives anticonvulsant effects. The pharmacological samples were examined for their ability to prevent convulsions using the strychnine-induced convulsion method.

Materials and Methods

Benzoin; Benzil; Urea; Glacial Acetic Acid; 4- amino benzoic acid; Con. HNO3; Formic Acid; 2- Nitro Aniline; 4- Nitro Aniline; Aniline; Acetyl Chloride; Formic Acid; 4- amino Phenol are used for the synthesis.IR, NMR and MS are used for interpretation.

Results

Our research led us to the conclusion that a variety of compounds have strong anticonvulsant properties. The compound 4-(2-chloro-N-(2-phenoxymethyl) aniline)-3-[2,4-dioxo-5,5-diphenylimidazolidine-1-yl) carbonyl] sulfonic acid (SSW5)- (scheme II A); 4-(3-chloro-N-(2-phenoxymethyl)aniline)-3-[2,4-dioxo-5,5-diphenylimidazolidine-1-yl) carbonyl] sulfonic acid (SSW6)- (scheme II A); 4-(2,5-dichloro-N-(2-phenoxymethyl)aniline)- 3-[2,4-dioxo-5,5-diphenylimidazolidine-1-yl) carbonyl] sulfonic acid (SSW7) (scheme II A) and 4-(N-(2-phenoxymethyl)aniline)-3-[2,4-dioxo-5,5-diphenylimidazolidine-1-yl) carbonyl] sulfonic acid (SSW3) (scheme II A) gives strong anti-convulsant effects against phenytoin drug.

Conclusion

The title compounds and its derivatives were examined for their ability to treat convulsions. Studies of the relationship between structure and activity revealed that compounds containing 5, 5-diphenylimidazolidine derivatives that have an electron-withdrawing group have higher activity than those that have an electron-donating group.